<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104202">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01907061</url>
  </required_header>
  <id_info>
    <org_study_id>007-157</org_study_id>
    <nct_id>NCT01907061</nct_id>
  </id_info>
  <brief_title>Acute Renal Failure Post Liver Transplantation</brief_title>
  <official_title>Acute Renal Failure Post Liver Transplantation: The Role of Cytokines and Oxidative Stress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial to test the effect of administering N-acetylcysteine on cytokines and markers of
      oxidant stress and the incidence of acute renal failure post liver tranplant
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To determine levels of pro-inflammatory cytokines and oxidative stress markers in liver
           transplant patients during post-transplant period

        2. To correlate changes in pro-inflammatory cytokines and markers of oxidative stress to
           acute renal failure and acute rejection

        3. To determine the impact of using N-acetylcysteine on cytokines and markers of oxidative
           stress and the incidence of acute renal failure post liver transplantation
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To determine levels of pro-inflammatory cytokines and oxidative stress markers in liver transplant patients during post-transplant period</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cytokines in patients receiving N-acetylcysteine versus those receiving placebo during liver transplantation will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To correlate changes in pro-inflammatory cytokines and markers of oxidative stress to acute renal failure and acute rejection</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>F2-isoprostanes levels in the two groups will be compared to evaluate the role in acute renal failure and acute rejection in patients recieving a liver transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iTo determine the impact of using N-acetylcysteine on cytokines and markers of oxidative stress and the incidence of acute renal failure post liver transplantation</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>N-acetylcysteine or placebo will be given to patients recieving a liver tranplant cytokines and oxidative stress markers will be compared between the two groups to determine if N-acetylcysteine will impact acute renal failure post liver transplantation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Renal Failure</condition>
  <arm_group>
    <arm_group_label>600 mg N-acetylcysteine or placebo IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg N-acetylcysteine or placebo IV perfused over 15 minutes during the transplant procedure, prior to reperfusion,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg N-acetylcysteine or placebo NG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg NAC or placebo administered via NG tube starting at 12 hrs  +  30 min post O.R. infusion,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine or placebo q 12 hour</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg NAC or placebo administered via NG tube every 12 hrs + 30 min for 3 additional doses (at 24, 36 and 48 hrs post O.R. infusion). The total administration will be 3000 mg over a 48 hr period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>drug will be administered via IV,NG</description>
    <arm_group_label>600 mg N-acetylcysteine or placebo IV</arm_group_label>
    <arm_group_label>600 mg N-acetylcysteine or placebo NG</arm_group_label>
    <arm_group_label>N-acetylcysteine or placebo q 12 hour</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo or NAC will be given</description>
    <arm_group_label>600 mg N-acetylcysteine or placebo IV</arm_group_label>
    <arm_group_label>600 mg N-acetylcysteine or placebo NG</arm_group_label>
    <arm_group_label>N-acetylcysteine or placebo q 12 hour</arm_group_label>
    <other_name>Placebo in place of NAC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First liver transplant

          -  Normal renal function before transplantation [serum creatinine  â‰¤ 1.5 mg / dl]

          -  No requirements for dialysis before transplantation

          -  Age greater than 18 years

        Exclusion Criteria:

          -  Re-transplant

          -  Renal dysfunction i.e. serum creatinine &gt; 1.5 mg/dl

          -  Need for dialysis before transplantation

          -  Presence of Hepatorenal or Hepatopulmonary syndrome*

          -  Combined liver and kidney transplant

          -  Peptic ulcer disease

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>71 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yousri M. Barri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Annette C. and Harold C. Simmons Tranplant Institute at Baylor Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>November 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute renal failure</keyword>
  <keyword>post liver transplant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
